August 13, 2013
1 min read
Save

Solutis SLT system cleared for clinical use

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The U.S. Food and Drug Administration has cleared Quantel Medical’s Solutis selective laser trabeculoplasty system for clinical use, according to a news release.

SLT is designed to function as a first-line or adjunct therapy to noninvasively reduce IOP in primary open-angle glaucoma patients via targeted laser energy.

Quantel has marketed the device outside the United States since 2007, but had been restricted from marketing within the United States due to a patent held by Massachusetts General Hospital that has since expired.